Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail targets Hard-to-Treat blood cancers

NCT ID NCT02328014

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times

Summary

This study tested a combination of two experimental drugs, acalabrutinib and ACP-319, in 40 people with B-cell blood cancers like non-Hodgkin lymphoma and multiple myeloma. The goal was to see if the combo is safe and shrinks tumors. Participants had to have a confirmed diagnosis and be well enough for treatment. The study is complete, but results are not yet public.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Orange, California, 92868, United States

  • Research Site

    Bethesda, Maryland, 20892, United States

  • Research Site

    Rochester, New York, 14642, United States

  • Research Site

    Portland, Oregon, 97239, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Austin, Texas, 78705, United States

  • Research Site

    Seattle, Washington, 98109, United States

Conditions

Explore the condition pages connected to this study.